Abstract:Purpose: Chronic Myeloid Leukemia (CML) is a clonal disorder of the hematopoietic stem cell caused by expression of the BCR::ABL1 oncoprotein. High BCR::ABL1 levels have been associated to proliferative advantage of leukemic cells, blast crisis progression and tyrosine kinase inhibitors (TKIs) inefficacy. We have previously shown that high BCR::ABL1/GUSIS transcripts measured at diagnosis are associated with inferior responses to standard dose Imatinib (IM). However, the mechanisms underlying the higher rates of disease progression and development of TKIs resistance dependent on elevated BCR::ABL1 levels remain unclear. Methods: Leukemic cells were collected from CML patients showing, at diagnosis, high or low BCR::ABL1/GUSIS. BCR::ABL1 expression levels were measured using real-time PCR. Short-term culture and long-term culture-initiating cells assays were employed to investigate the role of BCR::ABL1 gene-expression levels on proliferation, clonogenicity, signal transduction, TKIs responsiveness and self-renewal ability. Cell division was performed by carboxyfluorescein-succinimidyl ester (CFSE) assay. Results: We found that BCR::ABL1 oncogene expression levels correlate in both PMNs and CD34+ cells. Furthermore, high oncogene levels increased both proliferation and anti-apoptotic signaling via ERK and AKT phosphorylation. Moreover, high BCR::ABL1 expression reduced the clonogenicity of leukemic CD34+ cells and increased their sensitivity to high doses IM but not to those of dasatinib. Furthermore, we observed that high BCR::ABL1 levels are associated with a reduced self-renewal of primitive leukemic cells and, also, that these cells showed comparable TKIs responsiveness with cells expressing lower BCR::ABL1 levels. Interestingly, we found a direct correlation between high BCR::ABL1 levels and reduced number of quiescent leukemic cells caused by increasing their cycling. Conclusion: Higher BCR::ABL1 levels improving the proliferation, anti-apoptotic signaling and reducing self-renewal properties cause an increased expansion of leukemic clone.

Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

[Cytogenetic and Molecular Analysis of 1193 Cases with Chronic Myeloid Leukemia].

Early BCR-ABL1 Decline in Imatinib-Treated Patients with Chronic Myeloid Leukemia: Results from a Multicenter Study of the Chinese CML Alliance

Cytogenetic Analysis of 1863 Chineses Patients with Chronic Myeloid Leukemia

Study on relationship between different bcr/abl fusion transcripts and clinical manifestations in chronic myeloid leukemia]

Types of BCR-ABL Fusion Gene in Chronic Myeloid Leukemia and Its Clinical Significance

Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia

Clinical Significance of Detection of bcr/abl Fusion Gene in theDiagnosis and Minimal Residual Disease of Chronic Myeloid Leukemia

Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival

[Effect of Co-Expressing M-bcr/abl and M-Bcr/abl Fusion Gene Transcripts on the Clinical Features of Patients with Chronic Myelogenous Leukemia at Diagnosis].

[Clinical and Laboratory Characteristics of 12 Ph/BCR-ABL Positive Acute Myeloid Leukemia Patients].

High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability

Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology

The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia

Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis

Association Between the Concentration of Imatinib in Bone Marrow Mononuclear Cells, Mutation Status of Abcb1 and Therapeutic Response in Patients with Chronic Myelogenous Leukemia

Progress of the BCR-ABL and Src family kinases interactions leading CML to imatinib-resistance

Prevalence and Outcomes of Uncommon BCR‐ABL1 Fusion Transcripts in Patients with Chronic Myeloid Leukaemia: Data from a Single Centre

Comparative Clinical Study of Philadelphia Chromosome -Positive Acute Lymphoblastic Leukemia and Lymphoid Blast Crisis of Chronic Myelogenous Leukemia